Recombinant Xenopus laevis E3 ubiquitin-protein ligase MARCH2 (41335)

What is Xenopus laevis E3 ubiquitin-protein ligase MARCH2?

E3 ubiquitin-protein ligase MARCH2 is a member of the membrane-associated RING-CH-type finger (MARCH) family of proteins. In Xenopus laevis (African clawed frog), MARCH2 functions as an E3 ligase that facilitates the transfer of ubiquitin to target proteins, marking them for degradation or altering their cellular functions. The protein contains an N-terminal RING-CH domain followed by transmembrane domains and is also known as Membrane-associated RING finger protein 2 or Membrane-associated RING-CH protein II (MARCH-II) . The full-length protein consists of 246 amino acid residues and has the UniProt accession number Q5PQ35 .

How does MARCH2 relate to other members of the MARCH family?

MARCH2 belongs to the MARCH family, which consists of 11 members in mammals. These proteins evolved from viral homologs found in Kaposi's sarcoma-associated herpesvirus (KSHV) and are characterized by their RING-CH domains and transmembrane segments . While MARCH8 (formerly c-MIR) was the first identified human MARCH protein, all family members possess RING-CH domains with E3 ubiquitin ligase activity .

The MARCH family plays diverse roles in cellular processes, particularly in immune regulation. For instance, MARCH1 and MARCH8 regulate MHC-II expression, with MARCH8-mediated polyubiquitination of MHC-II being regulated by CD83 . Like other family members (MARCH5-8 and MARCH10), MARCH2's stability is tightly regulated by its RING-CH finger-mediated autoubiquitination .

What are the specific cellular functions of MARCH2 in protein trafficking?

MARCH2 plays a critical role in the early secretory pathway between the endoplasmic reticulum (ER) and Golgi compartments. Research has shown that MARCH2 directs the ubiquitination and subsequent degradation of ERGIC3 (ER-Golgi intermediate compartment protein 3), an ortholog of yeast Erv46 that functions as a cargo receptor .

Through this regulatory mechanism, MARCH2 affects the trafficking of ERGIC3-binding secretory proteins. Specifically, studies have demonstrated that:

• MARCH2 targets lysine residues at positions 6 and 8 of ERGIC3 for ubiquitination

• MARCH2 depletion increases endogenous ERGIC3 levels

• MARCH2 expression reduces secretion of α1-antitrypsin and haptoglobin

• Ubiquitination-resistant ERGIC3 variants can restore secretion of these cargo proteins

These findings indicate that MARCH2's regulation of ERGIC3 is a key control point in the early secretory pathway, affecting the trafficking and secretion of specific cargo proteins.

How does MARCH2 compare structurally and functionally to CRL2Lrr1 in Xenopus laevis?

While both MARCH2 and CRL2Lrr1 are E3 ubiquitin ligases found in Xenopus laevis, they differ significantly in structure, targets, and cellular functions:

CRL2Lrr1 specifically functions in DNA replication termination by ubiquitylating the Mcm7 subunit when replisomes from neighboring origins converge. This polyubiquitylated CMG is then disassembled by the p97 ATPase, leading to replication termination . In contrast, MARCH2 primarily regulates protein trafficking through the secretory pathway .

What role does MARCH2 play in cardiac pathology and inflammatory responses?

Recent research has identified MARCH2 as a protective factor in myocardial ischemia-reperfusion (I/R) injury. Single-cell RNA sequencing (scRNA-seq) of heart samples from mice with myocardial I/R injury revealed upregulation of MARCH2, which localizes primarily to the endoplasmic reticulum, endosome, Golgi apparatus, mitochondria, and plasma membranes .

MARCH2 ameliorates myocardial I/R injury through a mechanism involving:

• Interaction with phosphoglycerate mutase family member 5 (PGAM5)

• Promotion of K48-linked ubiquitination and degradation of PGAM5

• Inhibition of phase-separated condensates of PGAM5-mitochondrial anti-viral-signaling protein (MAVS)

• Subsequent suppression of NLRP3 inflammasome activation

These findings suggest that MARCH2 plays a crucial role in regulating inflammatory responses in cardiac tissue and may represent a novel therapeutic target for myocardial I/R injury.

What are the optimal conditions for handling recombinant Xenopus laevis MARCH2 protein?

For optimal handling and storage of recombinant Xenopus laevis E3 ubiquitin-protein ligase MARCH2, researchers should follow these guidelines:

• Storage conditions:

  • Store at -20°C for routine use

  • For extended storage, conserve at -20°C or -80°C

  • Avoid repeated freezing and thawing

• Working solution preparation:

  • Prepare working aliquots and store at 4°C for up to one week

  • The protein is typically provided in a Tris-based buffer with 50% glycerol, optimized for stability

• Handling precautions:

  • Thaw on ice when removing from freezer

  • Centrifuge briefly before opening to ensure all material is at the bottom of the tube

  • Use sterile technique when handling to prevent contamination

Following these guidelines will help maintain the structural integrity and enzymatic activity of the recombinant protein for experimental use.

What experimental approaches can be used to study MARCH2-mediated ubiquitination of target proteins?

Several methodological approaches can be employed to investigate MARCH2-mediated ubiquitination:

• Co-immunoprecipitation (Co-IP) assays:

  • Express tagged versions of MARCH2 and potential target proteins

  • Perform Co-IP to detect protein-protein interactions

  • Use western blotting with anti-ubiquitin antibodies to detect ubiquitinated species

• Site-directed mutagenesis:

  • Generate MARCH2 variants with mutations in the RING-CH domain to create catalytically inactive controls

  • Create lysine-to-arginine substitutions in target proteins to identify specific ubiquitination sites (as demonstrated with ERGIC3 K6R/K8R mutations)

• Ubiquitination assays:

  • In vitro ubiquitination using purified components (E1, E2, MARCH2, ubiquitin, ATP, and substrate)

  • Cell-based ubiquitination assays with HA-tagged ubiquitin to track ubiquitination events

• Functional readouts:

  • Measure protein degradation rates using cycloheximide chase assays

  • Monitor protein secretion (for secretory pathway cargo proteins)

  • Assess target protein localization using immunofluorescence or subcellular fractionation

These approaches can be combined to provide comprehensive insights into MARCH2's ubiquitination targets and the functional consequences of these modifications.

How can researchers effectively use MARCH2 knockout or overexpression systems to study its function?

To investigate MARCH2 function through genetic manipulation, researchers can implement the following methodological approaches:

• MARCH2 knockout systems:

  • CRISPR/Cas9-mediated gene editing to generate knockout cell lines or animal models

  • siRNA or shRNA for transient knockdown studies

  • Analysis of endogenous ERGIC3 levels as a positive control for successful MARCH2 depletion

  • For in vivo studies, utilize MARCH2 KO mouse models to investigate phenotypes such as response to myocardial I/R injury

• MARCH2 overexpression systems:

  • Transient transfection with tagged MARCH2 constructs

  • Viral vector-mediated overexpression (e.g., AAV9-cTnT-MARCH2 for cardiac-specific expression)

  • Inducible expression systems to control timing and level of expression

  • Co-expression with potential substrate proteins to assess direct effects

• Readout systems for functional analysis:

  • For protein trafficking studies: monitor secretion of α1-antitrypsin and haptoglobin as model cargo proteins

  • For cardiac protection studies: measure infarct size, cardiac function, and inflammasome activation markers

  • Biochemical analysis of PGAM5 ubiquitination and degradation in MARCH2 overexpression models

• Control experiments:

  • Utilize catalytically inactive MARCH2 mutants as negative controls

  • Perform rescue experiments by reintroducing wild-type or mutant MARCH2 into knockout backgrounds

  • Include appropriate tissue-specific controls when using in vivo models

These approaches provide complementary strategies to dissect MARCH2 function across different biological contexts.

What techniques can be used to investigate the MARCH2 interactome and identify novel substrates?

To comprehensively map the MARCH2 interactome and identify novel substrates, researchers can employ several advanced techniques:

• Mass spectrometry-based approaches:

  • Proximity-dependent biotin identification (BioID) or TurboID with MARCH2 as the bait protein

  • Stable isotope labeling with amino acids in cell culture (SILAC) combined with immunoprecipitation

  • Global protein stability profiling following MARCH2 manipulation

  • Ubiquitin remnant profiling to identify ubiquitination sites affected by MARCH2 expression

• Protein-protein interaction screening:

  • Yeast two-hybrid screening with MARCH2 as bait

  • Protein complementation assays (e.g., split luciferase)

  • Co-immunoprecipitation followed by mass spectrometry

• Validation of potential substrates:

  • Direct binding assays with recombinant proteins

  • In vitro and in vivo ubiquitination assays

  • Mutational analysis of potential ubiquitination sites

  • Assessment of protein stability and degradation in response to MARCH2 expression

• Functional classification of interactors:

These methodologies, especially when applied in combination, can reveal the full spectrum of MARCH2 substrates and interaction partners across different cellular contexts.